

12-8108: Anti-Human VEGF (Bevacizumab) – Biotin

Clonality :	Monoclonal
Clone Name :	A4.6.1
Application :	ELISA
Reactivity :	Human
Alternative Name :	Vascular Endothelial Growth Factor; VEGF-A; VEGFA; Vascular Permeability Factor; VPF
Isotype :	Human IgG1k
Immunogen Information :	Recombinant human VEGF.

Description

Expression Host : HEK-293

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only. Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.¹ Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.

Product Info

Amount :	100 µg Concentration : 0.5 mg/ml
Content :	This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage condition :	This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Application Note

The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 µg per 10⁶ cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.ELISA